Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience

Blood

Volumn 96, Issue 4, 2000, Pages 1259-1266

  Kaminski, M S ^a   Estes, J ^a   Zasadny, K R ^a   Francis, I R ^a   Ross, C W ^a   Tuck, M ^a   Regan, D ^a   Fisher, S ^a   Gutierrez, J ^a   Kroll, S ^a   Stagg, R ^a   Tidmarsh, G ^a   Wahl, R L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT; IODINE 131; TOSITUMOMAB; UNCLASSIFIED DRUG; CD20 ANTIGEN; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; WHOLE BODY RADIATION; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RADIOIMMUNOTHERAPY; RECURRENT DISEASE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; RECURRENCE; TREATMENT OUTCOME;

EID: 0034662510     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.4.1259     Document Type: Article

References (56)

1. Treatment of non-Hodgkin's lymphoma
2. Natural history of and therapy for the indolent non-Hodgkin's lymphomas
3. Follicular lymphoma: Prognostic factors for response and survival
4. High-dose therapy and transplantation in non-Hodgkin's lymphoma
5. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma
6. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation
7. A clinical trial of anti-idiotype therapy for B cell malignancy
8. Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon
9. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen
10. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas
11. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype
12. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
13. Characterization of a human B lymphocyte-specific antigen
14. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple trans-membrane domains
15. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies
16. Retention of B-cell specific monoclonal antibodies by human lymphoma cells
17. Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes
18. CD20: A regulator of cell-cycle progression of B lymphocytes
19. Therapy with unlabeled and I-131-labeled pan B-cell monoclonal antibodies in nude mice bearing Raji Burkitt lymphoma xenografts
20. The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines
21. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
22. Characterization of the apoptotic process initiated by ligation of CD20 by the mouse monoclonal antibody Anti-B1 in the Burkitt's lymphoma cell line Ramos
23. Radioimmunotherapy of B-cell lymphoma with [Iodine-131]anti-B1 (anti-CD20) antibody
24. I-131-Anti-B1 radioimmunotherapy for B-cell lymphoma
25. Iodine-131 Anti-B1 Antibody for B-cell lymphoma: An update on the Michigan Phase I experience
26. Protein and cell membrane iodinations with a sparingly soluble chloramide, 1,2,3,6-tetrachloro-3a,6a-diphrenylglycoluril
27. Inhibition of autoradiolysis of radiolabeled monoclonal antibodies by cryopreservation
28. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma
29. Patient-specific whole body dosimetry: Principles and a simplified method for clinical implementation
30. Non-parametric estimation from incomplete observations
31. Evaluation of survival data and two new rank order statistics arising in its consideration
32. Regression models and life tables
33. Note on the sampling error of the difference between correlated proportions or percentages
34. The comparison of survival curves
35. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage: The Non-Hodgkin's Lymphoma Pathologic Classification Project
36. Bladder cancer after chemotherapy for non-Hodgkin's lymphoma
37. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: Further evidence for characteristic abnormalities of chromosomes no. 5 and 7
38. Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using an I-131 labeled monoclonal antibody: An Illinois Cancer Council Study
39. Fractionated radioimmunotherapy of B-cell malignancies with I-131 Lym-1 monoclonal antibodies
40. Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia
41. Maximum-tolerated dose, toxicity, and efficacy of I-131 Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma
42. A phase I escalating-dose safety, dosimetry, and efficacy study of radiolabeled monoclonal antibody Lym-1
43. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody
44. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric or humanized LL2, an anti-CD22 monoclonal antibody
45. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma
46. Radioimmunotherapy of relapsed B-cell lymphoma with Yttrium 90 anti-idiotype monoclonal antibodies
47. Radiolabeled antibody therapy of B-cell lymphoma with autologous bone marrow support
48. Phase II trial of Iodine-131-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas
49. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue
50. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma
51. Therapeutic index of IDEC-Y2B8 radioimmunotherapy: Up to 850 fold greater radiation dose to tumor than to normal organs
52. Revised Nuclear Regulatory Commission regulations for release of patients administered radioactive materials: Outpatient iodine-131 anti-B1 therapy
53. Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy
54. A multicenter phase II study of Iodine-131 anti-B1 antibody (Bexxar) in patients with chemotherapy-relapsed/refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphoma
55. Multicenter, phase III study of iodine-131 tositumomab (Anti-B1 Antibody) for chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin's lymphoma
56. Front-line treatment of advanced B-cell low-grade lymphoma with radiolabeled anti-B1 antibody: Initial experience